<style> .wpb_animate_when_almost_visible { opacity: 1; }</style>


HLS Therapeutics is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. We focus on products targeting the central nervous system and cardiovascular therapeutic areas. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. HLS Therapeutics listed publicly on the TSXV in March 2018 by way of a reverse takeover of Automodular Corporation. On February 7, 2019, HLS Therapeutics graduated from the TSXV and its shares began trading on the TSX exchange.

Thursday, August 11, 2022
8:30am - 9:30am EDT

View All


The information contained on the Investor Relations section of this website was accurate at the time of posting, but may be superseded by subsequent disclosures. Please check the date of the material posted.

Aug 2, 2022

Reimbursement coverage for Vascepa in Canada is now approximately 70% for publicly covered lives and private coverage is now in excess of 95% for those that are in-label Public reimbursement for...

Jul 28, 2022

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2022 financial results on Thursday, August 11, 2022. The Company will hold a conference call...

Jul 25, 2022

Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in-label Public reimbursement for Vascepa is now...

Read More